Galapagos (GLPG)

• Market cap: $1.69B
• 1 day: 0.00%
• 5 days: -9.65%
• 1 month: -5.73%
• 3 months: -12.25%
• 6 months: -3.75%
• Year to date: -8.06%
• 1 year: -36.51%
• 5 years: -87.93%
• 10 years: -49.21%

About: Galapagos NV is a fully integrated biotechnology company focused on discovering, developing, and commercializing medicines. The company is committed to improving patients' lives world-wide by targeting diseases with high unmet needs. Its R&D capabilities cover multiple drug modalities, including small molecules and cell therapies. Its portfolio comprises discovery through to commercialized programs in immunology, oncology, and other indications. Its first medicine for rheumatoid arthritis and ulcerative colitis is available in Europe and Japan. It derives maximum revenue from United States of America.

Employees: 646

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

1,050% more call options, than puts

Call options by funds: $15.5M | Put options by funds: $1.34M

4% more repeat investments, than reductions

Existing positions increased: 25 | Existing positions reduced: 24

0% more funds holding in top 10

Funds holding in top 10: 4 [Q2] → 4 (+0) [Q3]

8% less funds holding

Funds holding: 85 [Q2] → 78 (-7) [Q3]

9.87% less ownership

Funds ownership: 30.43% [Q2] → 20.55% (-9.87%) [Q3]

22% less capital invested

Capital invested by funds: $497M [Q2] → $390M (-$107M) [Q3]

35% less first-time investments, than exits

New positions opened: 11 | Existing positions closed: 17

Research analyst outlook

1 Wall Street Analyst provided 1 year price targets over the past 3 months

• Low target: $30 17% upside
• Avg. target: $30 17% upside
• High target: $30 17% upside

1 analyst rating

• positive: 0 0%
• neutral: 1 100%
• negative: 0 0%

RBC Capital Brian Abrahams 20% 1-year accuracy 16 / 79 met price target

17% upside $30

Sector Perform Maintained

1 Nov 2024